The long-term trend of the EPS is an important number as it indicates the present value of Amyris. The EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been -23.60% over the last twelve months. The higher the EPS growth rate, the higher the value that is added to shareholders and a good reflection on the performance of the management at Amyris.

Amyris trades as part of the basic materials sector and is in the chemicals industry. The company CEO is John Melo. Amyris Inc is an industrial biotechnology company engaged in the engineering, manufacturing, and sales of products in markets such as cosmetics, flavors and fragrances, solvents and cleaners, polymers, lubricants, healthcare products, and fuels.

Previous Intraday Performance:

The AMRS shares had a previous change of 4.59% which opened at 5.50 and closed at 5.70. It moved to an intraday high of 6.06 and a low of 5.37.

SeekingAlpha:  Amyris Soars On CBD Deal

Historical Performance:

Over the last five trading days, AMRS shares returned 80.38% and in the past 30 trading days it returned 64.74%. Over three months, it changed -2.73%. In one year it has changed 12.43% and within that year its 52-week high was 9.29 and its 52-week low was 2.64. AMRS stock is 115.91% above its 52 Week Low.

Our calculations result in a 200 day moving average of 6.03 and a 50 day moving average of 3.95. Right now, AMRS stock is trading -5.54% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  Amyris Soars On CBD Deal


The company has a market cap of $419.3m with 73.6m shares outstanding and a float of 58.9m shares. Trading volume was 9,415,922 shares and has experienced an average volume of 3,595,496 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Amyris was -3.08 which ended on 31st of December 2017. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.42.

Below was the last reported quarterly earnings per share:
09-30-2018:  -1.67
06-30-2018:  -0.32
03-31-2018:  -1.79
12-31-2017:  -0.17

Base on our calculations, the intrinsic value per share is 17.89, which means it might be undervalued and has a margin of safety of 68.14%

Indicators Also to Watch:

Based on the latest filings, there is 39.00% of institutional ownership.

I calculated the beta to be 0.18

SeekingAlpha:  58 Stocks Going Ex-Dividend Next Week (Oct. 30th-Nov. 3rd)

Fundamental Numbers:

Based on last reported financials, the company’s return on assets is -124.90%, price-to-sales is 10.04 and price-to-book is 321.07.

Company Score Card:

Results are out of six:
 5  : Growth Expectations Result
 0  : Financial Safety Result
 0  : Past Performance Result
 2  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here